Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Aclaris Therapeutics Stock Forecast NASDAQ:ACRS
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2021-06-16 | 353.31% | HC Wainwright & Co. | $40.00 $50.00 | Maintains | Buy |
| 2021-06-15 | 171.99% | Piper Sandler | $30.00 | Initiates Coverage On | Overweight |
| 2021-04-21 | 262.65% | HC Wainwright & Co. | $40.00 | Initiates Coverage On | Buy |
| 2021-03-04 | 135.72% | SVB Leerink | $21.00 $26.00 | Maintains | Outperform |
| 2021-01-20 | 90.39% | SVB Leerink | $4.50 $21.00 | Maintains | Outperform |
| 2019-10-23 | - | SVB Leerink | - | Upgrades | Market Perform Outperform |
| 2019-10-22 | - | SVB Leerink | - | Upgrades | Market Perform Outperform |
| 2019-09-06 | - | JMP Securities | - | Downgrades | Market Outperform Market Perform |
| 2019-08-09 | -54.67% | Cantor Fitzgerald | $24.00 $5.00 | Reiterates | Overweight |
| 2019-06-27 | - | SVB Leerink | - | Downgrades | Outperform Market Perform |
ACRS Stock Trend
The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $10.00 is broken, it will firstly indicate a stronger fall rate.
Given the current short-term trend, the stock is expected to fall -17.04% during the next 3 months and, with a 90% probability hold a price between $8.29 and $13.28 at the end of this 3-month period.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-18 | $9.94 | $12.94 | $15.95 |
| 2022-05-19 | $9.89 | $12.89 | $15.89 |
| 2022-05-20 | $9.83 | $12.83 | $15.84 |
| 2022-05-23 | $9.78 | $12.78 | $15.78 |
| 2022-05-24 | $9.72 | $12.73 | $15.73 |
| 2022-05-25 | $9.67 | $12.67 | $15.67 |
| 2022-05-26 | $9.61 | $12.62 | $15.62 |
| 2022-05-27 | $9.56 | $12.56 | $15.56 |
| 2022-05-31 | $9.50 | $12.51 | $15.51 |
| 2022-06-01 | $9.45 | $12.45 | $15.45 |
| 2022-06-02 | $9.39 | $12.40 | $15.40 |
| 2022-06-03 | $9.34 | $12.34 | $15.34 |
| 2022-06-06 | $9.28 | $12.29 | $15.29 |
| 2022-06-07 | $9.23 | $12.23 | $15.24 |
| 2022-06-08 | $9.17 | $12.18 | $15.18 |
| 2022-06-09 | $9.12 | $12.12 | $15.13 |
| 2022-06-10 | $9.06 | $12.07 | $15.07 |
| 2022-06-13 | $9.01 | $12.01 | $15.02 |
| 2022-06-14 | $8.95 | $11.96 | $14.96 |
| 2022-06-15 | $8.90 | $11.90 | $14.91 |
| 2022-06-16 | $8.85 | $11.85 | $14.85 |
| 2022-06-17 | $8.79 | $11.79 | $14.80 |
| 2022-06-21 | $8.74 | $11.74 | $14.74 |
| 2022-06-22 | $8.68 | $11.68 | $14.69 |
| 2022-06-23 | $8.63 | $11.63 | $14.63 |
| 2022-06-24 | $8.57 | $11.57 | $14.58 |
| 2022-06-27 | $8.52 | $11.52 | $14.52 |
| 2022-06-28 | $8.46 | $11.46 | $14.47 |
| 2022-06-29 | $8.41 | $11.41 | $14.41 |
| 2022-06-30 | $8.35 | $11.36 | $14.36 |
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription t... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 108 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
